What can we learn from Abdullah's case?
Suspect early and initiate treatment to
prevent mortality1,2,16
prevent mortality1,2,16
When a patient presents with nosocomial septic shock,
suspect an IFI. The mortality rate of patients with a
Candida bloodstream infection more than doubles when
treatment is delayed by 12–24 hours compared with
treatment within 12 hours of detection.*,**2
suspect an IFI. The mortality rate of patients with a
Candida bloodstream infection more than doubles when
treatment is delayed by 12–24 hours compared with
treatment within 12 hours of detection.*,**2
Consider Liposomal Amphotericin B treatment for
Candida infections13,14,17
Candida infections13,14,17
Liposomal Amphotericin B is a second-line treatment
option with effective fungicidal activity and good
penetration into deep‑seated compartments.13,15,17
option with effective fungicidal activity and good
penetration into deep‑seated compartments.13,15,17
Liposomal Amphotericin B demonstrates reduced
nephrotoxicity vs. other amphotericin B
formulations13,18–25
nephrotoxicity vs. other amphotericin B
formulations13,18–25
The liposomal delivery system reduces off-target toxicity
by encapsulating amphotericin B until it reaches the
fungal cell wall.20,23 Close monitoring of electrolytes and
renal function during Liposomal Amphotericin B treatment
is important, especially at escalated doses.13,18 Renal
adverse reactions may still occur.13
by encapsulating amphotericin B until it reaches the
fungal cell wall.20,23 Close monitoring of electrolytes and
renal function during Liposomal Amphotericin B treatment
is important, especially at escalated doses.13,18 Renal
adverse reactions may still occur.13
Be ready to take on a variety of fungal pathogens,
by treating promptly and broad with
Liposomal Amphotericin B®1,2,4,14,27–30
by treating promptly and broad with
Liposomal Amphotericin B®1,2,4,14,27–30
*Risk of hospital mortality was lower in patients treated within 12 hours (n=9) than patients treated after 12 hours (n=148) (11.1% vs.
33.1%, p=0.169).2
33.1%, p=0.169).2
**Retrospective cohort analysis of 157 hospitalised patients with a positive blood culture for Candida over a 4-year period. Among the hospitalised
non-survivors, the causes of death included sepsis and multi-organ failure not directly attributed to Candida infection (n=31), sepsis and multi-organ
failure directly attributed to Candida infection (n=11), cardiac arrest (n=6) and pulmonary embolism (n=2). The timing of antifungal therapy was
determined from when the first blood sample showing a positive culture for fungi was drawn to the time when antifungal treatment was first
administered to the patient.2
non-survivors, the causes of death included sepsis and multi-organ failure not directly attributed to Candida infection (n=31), sepsis and multi-organ
failure directly attributed to Candida infection (n=11), cardiac arrest (n=6) and pulmonary embolism (n=2). The timing of antifungal therapy was
determined from when the first blood sample showing a positive culture for fungi was drawn to the time when antifungal treatment was first
administered to the patient.2
